The role of hypomethylating agents in the treatment of elderly patients with AML

Journal of Geriatric Oncology

Volumn 5, Issue 1, 2014, Pages 89-105

  Al Ali, Haifa Kathrin ^a   Jaekel, Nadja ^a   Niederwieser, Dietger ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Acute myeloid leukemia; Azacitidine; Decitabine; Elderly

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYTARABINE; DNA;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL PRACTICE; COMORBIDITY; CYTOGENETICS; DISEASE FREE SURVIVAL; DNA METHYLATION; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; ELDERLY CARE; EUROPEAN UNION; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; G1 PHASE CELL CYCLE CHECKPOINT; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEALTH STATUS; HUMAN; INDIVIDUALIZATION; LOW DRUG DOSE; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ACUTE MYELOID LEUKEMIA; AZACITIDINE; DECITABINE; ELDERLY;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL CYCLE; CLINICAL TRIALS AS TOPIC; DNA METHYLATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; RETROSPECTIVE STUDIES;

EID: 84893697515     PISSN: 18794068     EISSN: 18794076     Source Type: Journal    
DOI: 10.1016/j.jgo.2013.08.004     Document Type: Review

References (100)

1. Klepin H.D., Balducci L. Acute myelogenous leukemia in older adults. Oncologist 2009, 14:222-232.
2. Lowenberg B. Prognostic factors in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001, 14:65-75.
3. Juliusson G., Antunovic P., Derolf A., Lehmann S., Mollgard L., Stockelberg D., et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009, 113:4179-4187.
4. Lowenberg B., Ossenkoppele G.J., van P.W., Schouten H.C., Graux C., Ferrant A., et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009, 361:1235-1248.
5. Stone R.M. The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin 2002, 52:363-371.
6. Jabbour E.J., Estey E., Kantarjian H.M. Adult acute myeloid leukemia. Mayo Clin Proc 2006, 81:247-260.
7. Menzin J., Lang K., Earle C.C., Kerney D., Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002, 162:1597-1603.
8. Burnett A.K., Milligan D., Prentice A.G., Goldstone A.H., McMullin M.F., Hills R.K., et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007, 109:1114-1124.
9. Sekeres M.A., Steensma D.P. Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia. J Clin Oncol 2012, 30:4061-4063.
10. Kroeger H., Jelinek J., Estecio M.R., He R., Kondo K., Chung W., et al. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood 2008, 112:1366-1373.
11. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Gattermann N., Germing U., et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010, 28:562-569.
12. Kantarjian H., Oki Y., Garcia-Manero G., Huang X., O'Brien S., Cortes J., et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007, 109:52-57.
13. Lubbert M., Suciu S., Baila L., Ruter B.H., Platzbecker U., Giagounidis A., et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011, 29:1987-1996.
14. Seymour J.F., Fenaux P., Silverman L.R., Mufti G.J., Hellstrom-Lindberg E., Santini V., et al. Effects of azacitidine compared with conventional care regimens in elderly (>/=75years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2010, 76:218-227.
15. Kantarjian H.M., Thomas X.G., Dmoszynska A., Wierzbowska A., Mazur G., Mayer J., et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012, 30:2670-2677.
16. European Medicines Agency: assessment report on Dacogen 19 July 2012 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002221/WC500133571.pdf.
17. Minutes for the February 9 2012 meeting of the FDA Oncologic Drugs Advisory Committee http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM293710.pdf.
18. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
19. Blum W., Garzon R., Klisovic R.B., Schwind S., Walker A., Geyer S., et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A 2010, 107:7473-7478.
20. Cashen A.F., Schiller G.J., O'Donnell M.R., DiPersio J.F. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010, 28:556-561.
21. Lubbert M., Ruter B.H., Claus R., Schmoor C., Schmid M., Germing U., et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica 2012, 97:393-401.
22. Al-Ali H.K., Jaekel N., Junghanss C., Maschmeyer G., Krahl R., Cross M., et al. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leuk Lymphoma 2012, 53:110-117.
23. Serrano J., de la Fuent A., Bergua J., et al. 5-Azacytidine versus intensive chemotherapy or BSC in elderly (>60years) AML patients: a retrospective analysis [abstract]. Blood 2011, 118(21):2612.
24. Sudan N., Rossetti J.M., Shadduck R.K., Latsko J., Lech J.A., Kaplan R.B., et al. Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer 2006, 107:1839-1843.
25. Pleyer L., Stauder R., Burgstaller S., Schreder M., Tinchon C., Pfeilstocker M., et al. Azacitidine in patients with WHO-defined AML: results of 155 patients from the Austrian Azacitidine Registry (AAR) of the AGMT study group. J Hematol Oncol 2013, 6:32.
26. Bories P., Bertoli S., Huguet F., Dobbelstein S., Fornecker L., Rauzy O.B., et al. Efficacy of frontline 5-azacytidine in older AML patients unfit for chemotherapy [abstract]. Blood 2011, 118(21):2614.
27. Kantarjian H., Ravandi F., O'Brien S., Cortes J., Faderl S., Garcia-Manero G., et al. Intensive chemotherapy does not benefit most older patients (age 70years or older) with acute myeloid leukemia. Blood 2010, 116:4422-4429.
28. Pollyea D.A., Kohrt H.E., Medeiros B.C. Acute myeloid leukaemia in the elderly: a review. Br J Haematol 2011, 152:524-542.
29. Sorror M.L., Maris M.B., Storb R., Baron F., Sandmaier B.M., Maloney D.G., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
30. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655.
31. Ramos F., Martinez-Robles V., Bargay J., Deben G., Garrido A., Serrano J., et al. Azacitidine as front-line therapy in AML: results from the Spanish National Registry. Alma Study Investigators [abstract]. Blood 2012, 120(21):3593.
32. Knipp S., Hildebrand B., Kundgen A., Giagounidis A., Kobbe G., Haas R., et al. Intensive chemotherapy is not recommended for patients aged >60years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer 2007, 110:345-352.
33. Farag S.S., Archer K.J., Mrozek K., Ruppert A.S., Carroll A.J., Vardiman J.W., et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006, 108:63-73.
34. Frohling S., Schlenk R.F., Kayser S., Morhardt M., Benner A., Dohner K., et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60years: results from AMLSG trial AML HD98-B. Blood 2006, 108:3280-3288.
35. Grimwade D., Walker H., Harrison G., Oliver F., Chatters S., Harrison C.J., et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98:1312-1320.
36. Maurillo L., Venditti A., Spagnoli A., Gaidano G., Ferrero D., Oliva E., et al. Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program. Cancer 2012, 118:1014-1022.
37. Arber D.A., Stein A.S., Carter N.H., Ikle D., Forman S.J., Slovak M.L. Prognostic impact of acute myeloid leukemia classification. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. Am J Clin Pathol 2003, 119:672-680.
38. Bernstein S.H., Brunetto V.L., Davey F.R., Wurster-Hill D., Mayer R.J., Stone R.M., et al. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study. J Clin Oncol 1996, 14:2486-2494.
39. Estey E., Thall P., Beran M., Kantarjian H., Pierce S., Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 1997, 90:2969-2977.
40. Lehmann S., Lazarevic V., Horstedt A.S., Hulegardh E., Nilsson C., Antunovic P., et al. Poor outcome in secondary acute myeloid leukemia (AML): a first report from the population-based Swedish Acute Leukemia Registry [abstract]. Blood 2012, 120(21):130.
41. Thepot S., Itzykson R., Seegers V., Raffoux E., Quesnel B., Chait Y., et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 2010, 116:3735-3742.
42. Kern W., Haferlach T., Schoch C., Loffler H., Gassmann W., Heinecke A., et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003, 101:64-70.
43. Wheatley K., Burnett A.K., Goldstone A.H., Gray R.G., Hann I.M., Harrison C.J., et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999, 107:69-79.
44. Goldstone A.H., Burnett A.K., Wheatley K., Smith A.G., Hutchinson R.M., Clark R.E. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98:1302-1311.
45. Stone R.M., Berg D.T., George S.L., Dodge R.K., Paciucci P.A., Schulman P.P., et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 2001, 98:548-553.
46. Grovdal M., Karimi M., Khan R., Aggerholm A., Antunovic P., Astermark J., et al. Maintenance treatment with azacitidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. Br J Haematol 2010, 150:293-302.
47. Silverman L.R., Fenaux P., Mufti G.J., Santini V., Hellstrom-Lindberg E., Gattermann N., et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 2011, 117:2697-2702.
48. Voso M.T., Breccia M., Lunghi M., Poloni A., Niscola P., Finelli C., et al. Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Eur J Haematol 2013, 90:345-348.
49. Estey E., Dohner H. Acute myeloid leukaemia. Lancet 2006, 368:1894-1907.
50. Breems D.A., van Putten W.L., Huijgens P.C., Ossenkoppele G.J., Verhoef G.E., Verdonck L.F., et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005, 23:1969-1978.
51. Gavillet M., Noetzli J., Blum S., Duchosal M.A., Spertini O., Lambert J.F. Transfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine. Haematologica 2012, 97:1929-1931.
52. Ganetsky A., Adel N.G., Frattini M.G., Maslak P.G., Heaney M.L., Jurcic J.G., et al. Decitabine for the treatment of acute myeloid leukemia (AML): Memorial Sloan-Kettering Cancer Center experience [abstract]. J Clin Oncol 2011, 29(Suppl. 15):6593.
53. George T.J., Woolery J.E., Wetzstein G.A., Ho V.Q., Lancet J.E., List A.F., et al. A Retrospective Study of Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia: Lack of Response Observed In a Heavily Pretreated Population [abstract]. Blood 2010, 116(21):2186.
54. Qin T., Jelinek J., Si J., Shu J., Issa J.P. Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines. Blood 2009, 113:659-667.
55. Bacher U., Talano J.A., Bishop M.R. Monitoring and prevention of relapse after allogeneic hematopoietic cell transplantation for myeloid malignancies. Biol Blood Marrow Transplant 2012, 18:S62-S73.
56. Aoudjhane M., Labopin M., Gorin N.C., Shimoni A., Ruutu T., Kolb H.J., et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005, 19:2304-2312.
57. de Lima M., Giralt S. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. Semin Hematol 2006, 43:107-117.
58. Estey E., de Lima M., Tibes R., Pierce S., Kantarjian H., Champlin R., et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007, 109:1395-1400.
59. Hegenbart U., Niederwieser D., Sandmaier B.M., Maris M.B., Shizuru J.A., Greinix H., et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006, 24:444-453.
60. Schetelig J., Bornhauser M., Schmid C., Hertenstein B., Schwerdtfeger R., Martin H., et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol 2008, 26:5183-5191.
61. Wong R., Giralt S.A., Martin T., Couriel D.R., Anagnostopoulos A., Hosing C., et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55years. Blood 2003, 102:3052-3059.
62. Craddock C., Jilani N., Siddique S., Vyas P., Goodyear O., Dennis M., et al. Azacitidine is well tolerated after allogeneic stem cell transplantation and its administration is associated with a reduced risk of acute graft-versus-host disease [abstract]. Haematologica 2012, 97(1):21.
63. De Lima M., Giralt S., Thall P.F., de Padua S.L., Jones R.B., Komanduri K., et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010, 116:5420-5431.
64. Jabbour E., Giralt S., Kantarjian H., Garcia-Manero G., Jagasia M., Kebriaei P., et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009, 115:1899-1905.
65. Platzbecker U., Wermke M., Radke J., Oelschlaegel U., Seltmann F., Kiani A., et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012, 26:381-389.
66. Bolaños-Meade J., Smith B.D., Gore S.D., McDevitt M.A., Luznik L., Fuchs E.J., et al. 5-Azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2011, 17:754-758.
67. Czibere A., Bruns I., Kroger N., Platzbecker U., Lind J., Zohren F., et al. 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant 2010, 45:872-876.
68. Graef T., Kuendgen A., Fenk R., Zohren F., Haas R., Kobbe G. Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine. Leuk Res 2007, 31:257-259.
69. Lubbert M., Bertz H., Wasch R., Marks R., Ruter B., Claus R., et al. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant 2010, 45:627-632.
70. Schroeder T., Czibere A., Kroger N., Platzbecker U., Bug G., Uharek L., et al. Phase II study of azacitidine and donor lymphocyte infusions as first salvage therapy in patients with acute myeloid leukemia or myelodysplastic syndromes relapsing after allogeneic HSCT: final results of the AZARELA study [abstract]. Blood 2011, 118(21):656.
71. Goodyear O.C., Dennis M., Jilani N.Y., Loke J., Siddique S., Ryan G., et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 2012, 119:3361-3369.
72. Santini V., Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Silverman L.R., List A., et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. Eur J Haematol 2010, 85:130-138.
73. Kornblith A.B., Herndon J.E., Silverman L.R., Demakos E.P., Odchimar-Reissig R., Holland J.F., et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002, 20:2441-2452.
74. Hollenbach P.W., Nguyen A.N., Brady H., Williams M., Ning Y., Richard N., et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 2010, 5:e9001.
75. Fandy T.E., Herman J.G., Kerns P., Jiemjit A., Sugar E.A., Choi S.H., et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009, 114:2764-2773.
76. Raj K., John A., Ho A., Chronis C., Khan S., Samuel J., et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 2007, 21:1937-1944.
77. Cross M., Bach E., Tran T., Krahl R., Jaekel N., Niederwieser D., et al. Pretreatment Long interspersed element (LINE)-1 methylation levels, not early hypomethylation under treatment, predict hematological response to azacitidine in elderly patients with acute myeloid leukemia. Onco Targets Ther 2013, 6:741-748. 10.2147/OTT.S45459.
78. Garcia-Manero G., Gore S.D., Kambhampati S., Scott B.L., Tefferi A., Cogle C.R., et al. Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes. Blood 2012, 120:424.
79. Yang A.S., Doshi K.D., Choi S.W., Mason J.B., Mannari R.K., Gharybian V., et al. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res 2006, 66:5495-5503.
80. Yan P., Frankhouser D., Murphy M., Tam H.H., Rodriguez B., Curfman J., et al. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood 2012, 120:2466-2474.
81. Li L.H., Olin E.J., Buskirk H.H., Reineke L.M. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res 1970, 30:2760-2769.
82. Cihak A., Weiss J.W., Pitot H.C. Characterization of polyribosomes and maturation of ribosomal RNA in hepatoma cells treated with 5-azacytidine. Cancer Res 1974, 34:3003-3009.
83. Lu L.J., Randerath K. Mechanism of 5-azacytidine-induced transfer RNA cytosine-5-methyltransferase deficiency. Cancer Res 1980, 40:2701-2705.
84. Reichman M., Penman S. The mechanism of inhibition of protein synthesis by 5-azacytidine in HeLa cells. Biochim Biophys Acta 1973, 324:282-289.
85. Qiu X., Hother C., Ralfkiaer U.M., Sogaard A., Lu Q., Workman C.T., et al. Equitoxic doses of 5-azacytidine and 5-aza-2'deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome. PLoS One 2010, 5:e12994.
86. Schaefer M., Hagemann S., Hanna K., Lyko F. Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines. Cancer Res 2009, 69:8127-8132.
87. Gorczyca W., Gong J., Ardelt B., Traganos F., Darzynkiewicz Z. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res 1993, 53:3186-3192.
88. Murakami T., Li X., Gong J., Bhatia U., Traganos F., Darzynkiewicz Z. Induction of apoptosis by 5-azacytidine: drug concentration-dependent differences in cell cycle specificity. Cancer Res 1995, 55:3093-3098.
89. Paul T.A., Bies J., Small D., Wolff L. Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML. Blood 2010, 115:3098-3108.
90. Aimiuwu J., Wang H., Chen P., Xie Z., Wang J., Liu S., et al. RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. Blood 2012, 119:5229-5238.
91. National Cancer Institute SEER Cancer Statistics Review 1975-2009 http://seer.cancer.gov/csr/1975_2009_pops09/.
92. Patel J.P., Gonen M., Figueroa M.E., Fernandez H., Sun Z., Racevskis J., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012, 366:1079-1089.
93. Schlenk R.F., Dohner K., Krauter J., Frohling S., Corbacioglu A., Bullinger L., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1909-1918.
94. Itzykson R., Thepot S., Quesnel B., Dreyfus F., Beyne-Rauzy O., Turlure P., et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011, 117:403-411.
95. Neil G.L., Berger A.E., Bhuyan B.K., DeSante D.C. Combination chemotherapy of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine and 5-azacytidine. Cancer Res 1976, 36:1114-1120.
96. Kong X.B., Tong W.P., Chou T.C. Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine. Mol Pharmacol 1991, 39:250-257.
97. Avramis V.I., Mecum R.A., Nyce J., Steele D.A., Holcenberg J.S. Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia. Cancer Chemother Pharmacol 1989, 24:203-210. 10.1007/BF00257619.
98. Krug U., Koschmieder A., Schwammbach D., Gerss J., Tidow N., Steffen B., et al. Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia - a randomised SAL pilot study. PLoS One 2012, 7(12):e52695. 10.1371/journal.pone.0052695.
99. Gourdin T.S., Bhatnagar B., Duffy A.P., Tidwell M., Ning Y., Sausville E.A., et al. Disease response and survival outcomes in acute myeloid leukemia (AML) patients unfit for chemotherapy treated with 10-day decitabine as initial therapy [abstract]. J Clin Oncol 2012, 30(Suppl. 15):611.
100. Fernandez A., Shah D., Liu D., Ahmed N., Lulaj E., Seiter K. High response rate and prolonged survival in patients with primary refractory acute myelogenous leukemia treated with decitabine salvage therapy [abstract]. Blood 2011, 118(21):4280.